Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
In the larger SELECT trial in 2023, patients with heart failure, atherosclerotic disease, and overweight or obesity, treated with semaglutide 2.4 mg showed reduction in major adverse cardiac events (MACE) and heart failure end points regardless of heart failure subgroup being HFrEF or HFpEF [56,57,58]
Their active ingredient, semaglutide, regulates appetite and makes the body feel fuller faster, reducing food intake
For type 2 diabetes, NICE (NG28) recommends continuing GLP-1 therapy only if patients achieve both a reduction in HbA1c of at least 11 mmol/mol (1.0%) AND at least 3% weight loss after 6 months
Therefore, the concept of offlabel use is inherently nuanced and demands careful explanation
Underuse of glp-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile
US$ 21.24
US$ 22.83
US$ 24.62
US$ 28.34
US$ 26.20
US$ 27.00
US$ 24.17
US$ 27.14
